Background: Hepatic vein embolization in double vein embolization (DVE) can be performed with transhepatic, transjugular or transfemoral access. This study evaluates the feasibility and technical success of using a transfemoral access for the hepatic vein embolization in patients undergoing preoperative to induce hypertrophy of the future liver remnant (FLR).
Material and methods: Retrospective analysis of single center cohort including 17 consecutive patients. The baseline standardized FLR was 18.2% (range 14.7-24.9). Portal vein embolization was performed with vascular plugs and glue through an ipsilateral transhepatic access. Hepatic vein embolization was performed using vascular plugs. Access for the hepatic vein was either transhepatic, transjugular or transfemoral. Technical success, number of hepatic veins embolized and complications were registered. In addition, volumetric data including degree of hypertrophy (DH) and kinetic growth rate (KGR), and resection data were registered. R: Seven of the 17 patients had transfemoral hepatic vein embolization, with 100% technical success. No severe complications were registered. In the whole cohort, the median number of hepatic veins embolized was 2 (1-6). DH was 8.6% (3.0-19.4) and KGR was 3.6%/week (1.4-7.4), without significant differences between the patients having transfemoral versus transhepatic /transjugular access (p = 0.48 and 0.54 respectively). Time from DVE to surgery was median 4.8 weeks (2.6-33.9) for the whole cohort, with one patient declining surgery, two having explorative laparotomy and one patient having change of surgical strategy due to insufficient growth.
Conclusion: Transfemoral access is a feasible option with a high degree of technical success for hepatic vein embolization in patients with small future liver remnants needing DVE.
{"title":"Transfemoral hepatic vein access in double vein embolization - initial experience and feasibility.","authors":"Ulrik Carling, Sigurd Berger, Eyvind Gjønnæss, Bård Røsok, Sheraz Yaqub, Kristoffer Lassen, Åsmund Avdem Fretland, Eric Dorenberg","doi":"10.1186/s42155-024-00478-y","DOIUrl":"10.1186/s42155-024-00478-y","url":null,"abstract":"<p><strong>Background: </strong>Hepatic vein embolization in double vein embolization (DVE) can be performed with transhepatic, transjugular or transfemoral access. This study evaluates the feasibility and technical success of using a transfemoral access for the hepatic vein embolization in patients undergoing preoperative to induce hypertrophy of the future liver remnant (FLR).</p><p><strong>Material and methods: </strong>Retrospective analysis of single center cohort including 17 consecutive patients. The baseline standardized FLR was 18.2% (range 14.7-24.9). Portal vein embolization was performed with vascular plugs and glue through an ipsilateral transhepatic access. Hepatic vein embolization was performed using vascular plugs. Access for the hepatic vein was either transhepatic, transjugular or transfemoral. Technical success, number of hepatic veins embolized and complications were registered. In addition, volumetric data including degree of hypertrophy (DH) and kinetic growth rate (KGR), and resection data were registered. R: Seven of the 17 patients had transfemoral hepatic vein embolization, with 100% technical success. No severe complications were registered. In the whole cohort, the median number of hepatic veins embolized was 2 (1-6). DH was 8.6% (3.0-19.4) and KGR was 3.6%/week (1.4-7.4), without significant differences between the patients having transfemoral versus transhepatic /transjugular access (p = 0.48 and 0.54 respectively). Time from DVE to surgery was median 4.8 weeks (2.6-33.9) for the whole cohort, with one patient declining surgery, two having explorative laparotomy and one patient having change of surgical strategy due to insufficient growth.</p><p><strong>Conclusion: </strong>Transfemoral access is a feasible option with a high degree of technical success for hepatic vein embolization in patients with small future liver remnants needing DVE.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"7 1","pages":"64"},"PeriodicalIF":1.2,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11371999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142121147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-14DOI: 10.1186/s42155-024-00475-1
Mohammed Shamseldin, Hendrik Heers, Thomas Steiner, Ralf Puls
Introduction: Ureterovascular fistula (UVF) is a rare but potentially life-threatening condition. Since its primary description by Moschkowitz in 1908, many case reports, studies and reviews have been written about this condition with the suggestive symptoms and risk factors repeatedly discussed. This study will be focusing on the different locations of 532 out of 605 fistulae published from 1908 up to 2022 besides eight new patients of our own.
Material and methods: A systematic review of the literature started using PubMed database searching for "ureteroarterial fistula", "arteriovascular fistula" and "uretero vascular fistula" was performed yielding 122, 62 and 188 results respectively. Those studies and the cited literature in each study were examined to include studies, which did not appear in the primary search. A total of 605 patients in 315 publications were gathered. Only studies mentioning new patients, a clear indication of the location of the UVF, the presence/absence of urinary diversion (UD) as well as the type of UD if present were included. Ten duplicates as well as studies lacking information regarding the UVF and/or the UD (seven publications with 63 patients) were excluded, with 298 publications including 532 external patients remaining. Eight internal cases were included with a total of 540 cases.
Results: From the 540 included cases, 384 patients (71.1%) had no UD compared to 156 patients (28.9%) with UD. Due to the anatomical ureteral course, the common iliac artery (CIA) was the most common vascular component of UVF, irrespective of the presence or absence of UD. Any dispute to whether the crossing point is the common or the external iliac artery (EIA) was settled for the CIA. Further common vascular components besides CIA include the aorta, EIA, internal iliac artery (IIA) including its branches and vascular bypasses including the anastomosis sites. Other unusual arterial localizations were stated under the "others" category.
Conclusion: Identifying the location of the bleeding artery in UVF is critical and represents the most important step for successful management. We present the largest summary of described locations up to date including our own.
{"title":"Anatomic locations of ureterovascular fistulae: a review of 532 patients in the literature and a new series of 8 patients.","authors":"Mohammed Shamseldin, Hendrik Heers, Thomas Steiner, Ralf Puls","doi":"10.1186/s42155-024-00475-1","DOIUrl":"10.1186/s42155-024-00475-1","url":null,"abstract":"<p><strong>Introduction: </strong>Ureterovascular fistula (UVF) is a rare but potentially life-threatening condition. Since its primary description by Moschkowitz in 1908, many case reports, studies and reviews have been written about this condition with the suggestive symptoms and risk factors repeatedly discussed. This study will be focusing on the different locations of 532 out of 605 fistulae published from 1908 up to 2022 besides eight new patients of our own.</p><p><strong>Material and methods: </strong>A systematic review of the literature started using PubMed database searching for \"ureteroarterial fistula\", \"arteriovascular fistula\" and \"uretero vascular fistula\" was performed yielding 122, 62 and 188 results respectively. Those studies and the cited literature in each study were examined to include studies, which did not appear in the primary search. A total of 605 patients in 315 publications were gathered. Only studies mentioning new patients, a clear indication of the location of the UVF, the presence/absence of urinary diversion (UD) as well as the type of UD if present were included. Ten duplicates as well as studies lacking information regarding the UVF and/or the UD (seven publications with 63 patients) were excluded, with 298 publications including 532 external patients remaining. Eight internal cases were included with a total of 540 cases.</p><p><strong>Results: </strong>From the 540 included cases, 384 patients (71.1%) had no UD compared to 156 patients (28.9%) with UD. Due to the anatomical ureteral course, the common iliac artery (CIA) was the most common vascular component of UVF, irrespective of the presence or absence of UD. Any dispute to whether the crossing point is the common or the external iliac artery (EIA) was settled for the CIA. Further common vascular components besides CIA include the aorta, EIA, internal iliac artery (IIA) including its branches and vascular bypasses including the anastomosis sites. Other unusual arterial localizations were stated under the \"others\" category.</p><p><strong>Conclusion: </strong>Identifying the location of the bleeding artery in UVF is critical and represents the most important step for successful management. We present the largest summary of described locations up to date including our own.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"7 1","pages":"63"},"PeriodicalIF":1.2,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141977166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-14DOI: 10.1186/s42155-024-00474-2
R Copping, N Ng, S Osman
Background: Bronchial artery pseudoaneurysms (BAP) or aneurysms (BAA) are rare, potentially life-threatening and remain poorly understood. They are most commonly idiopathic but may be associated with a number of other disease processes. Bronchial artery embolisation (BAE) is considered the first line treatment while surgical techniques are reserved for patients with a clear contraindication to embolisation or where anatomical factors preclude an endovascular approach.
Case presentation: We present an interesting case of a 56 year-old male presenting with an idiopathic unruptured right BAP causing clinical and radiological signs of left recurrent laryngeal nerve (RLN) palsy. He was otherwise clinically well with no other reported symptoms and no significant past medical history. There were no significant findings on work-up and investigation. He was ultimately treated successfully with selective transarterial coil embolization of the right bronchial artery. This is an atypical presentation of a rare clinical entity and has not previously been published in the literature to our knowledge.
Conclusions: BAPs and BAAs are highly variable in their presentation, ranging from incidental asymptomatic findings to catastrophic haemorrhage, depending on their location and if they are contained or ruptured. Timely diagnosis and referral to facilitate urgent embolisation is essential to prevent potentially serious clinical sequelae. Endovascular treatment in the form of BAE is considered first line.
{"title":"Selective embolisation of an idiopathic bronchial artery pseudoaneurysm presenting with recurrent laryngeal nerve palsy: a case report.","authors":"R Copping, N Ng, S Osman","doi":"10.1186/s42155-024-00474-2","DOIUrl":"10.1186/s42155-024-00474-2","url":null,"abstract":"<p><strong>Background: </strong>Bronchial artery pseudoaneurysms (BAP) or aneurysms (BAA) are rare, potentially life-threatening and remain poorly understood. They are most commonly idiopathic but may be associated with a number of other disease processes. Bronchial artery embolisation (BAE) is considered the first line treatment while surgical techniques are reserved for patients with a clear contraindication to embolisation or where anatomical factors preclude an endovascular approach.</p><p><strong>Case presentation: </strong>We present an interesting case of a 56 year-old male presenting with an idiopathic unruptured right BAP causing clinical and radiological signs of left recurrent laryngeal nerve (RLN) palsy. He was otherwise clinically well with no other reported symptoms and no significant past medical history. There were no significant findings on work-up and investigation. He was ultimately treated successfully with selective transarterial coil embolization of the right bronchial artery. This is an atypical presentation of a rare clinical entity and has not previously been published in the literature to our knowledge.</p><p><strong>Conclusions: </strong>BAPs and BAAs are highly variable in their presentation, ranging from incidental asymptomatic findings to catastrophic haemorrhage, depending on their location and if they are contained or ruptured. Timely diagnosis and referral to facilitate urgent embolisation is essential to prevent potentially serious clinical sequelae. Endovascular treatment in the form of BAE is considered first line.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"7 1","pages":"62"},"PeriodicalIF":1.2,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11322463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141977167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-10DOI: 10.1186/s42155-024-00473-3
Fernando M Gómez, Tarik R Baetens, Ernestos Santos, Boris León Rocha, Benjamín Horwitz, Sara Lojo-Lendoiro, Patricio Vargas, Premal Patel, Regina Beets-Tan, José J Martínez-Rodrigo, Luis Martí Bonmatí
The lymphatic circulation plays a crucial role in maintaining fluid balance and supporting immune responses by returning serum proteins and lipids to the systemic circulation. Lymphatic leaks, though rare, pose significant challenges post-radical neck surgery, oesophagectomy, and thoracic or retroperitoneal oncological resections, leading to heightened morbidity and mortality. Managing lymphatic leaks necessitates consideration of aetiology, severity, and volume of leakage. Traditionally, treatment involved conservative measures such as dietary restrictions, drainage, and medical management, with surgical intervention reserved for severe cases, albeit with variable outcomes and extended recovery periods. Lymphography, introduced in the 1950s, initially served as a diagnostic tool for lymphoedema, lymphoma, tumour staging, and monitoring chemotherapy response. However, its widespread adoption was impeded by alternative techniques like Computed Tomography, learning curves, and its associated complications. Contemporary lymphatic interventions have evolved, favouring nodal lymphangiography over pedal lymphangiography for its technical simplicity and reduced complexity. Effective management of chylous leaks mandates a multimodal approach encompassing clinical evaluation and imaging techniques. In cases where conservative management proves ineffective, embolization through conventional lymphangiography by bipedal dissection or intranodal injection emerges as a viable option. This review underscores the importance of a comprehensive approach to diagnosing and treating lymphatic leaks, highlighting advancements in imaging and therapeutic interventions that enhance patient outcomes.
{"title":"Interventional solutions for post-surgical problems: a lymphatic leaks review.","authors":"Fernando M Gómez, Tarik R Baetens, Ernestos Santos, Boris León Rocha, Benjamín Horwitz, Sara Lojo-Lendoiro, Patricio Vargas, Premal Patel, Regina Beets-Tan, José J Martínez-Rodrigo, Luis Martí Bonmatí","doi":"10.1186/s42155-024-00473-3","DOIUrl":"10.1186/s42155-024-00473-3","url":null,"abstract":"<p><p>The lymphatic circulation plays a crucial role in maintaining fluid balance and supporting immune responses by returning serum proteins and lipids to the systemic circulation. Lymphatic leaks, though rare, pose significant challenges post-radical neck surgery, oesophagectomy, and thoracic or retroperitoneal oncological resections, leading to heightened morbidity and mortality. Managing lymphatic leaks necessitates consideration of aetiology, severity, and volume of leakage. Traditionally, treatment involved conservative measures such as dietary restrictions, drainage, and medical management, with surgical intervention reserved for severe cases, albeit with variable outcomes and extended recovery periods. Lymphography, introduced in the 1950s, initially served as a diagnostic tool for lymphoedema, lymphoma, tumour staging, and monitoring chemotherapy response. However, its widespread adoption was impeded by alternative techniques like Computed Tomography, learning curves, and its associated complications. Contemporary lymphatic interventions have evolved, favouring nodal lymphangiography over pedal lymphangiography for its technical simplicity and reduced complexity. Effective management of chylous leaks mandates a multimodal approach encompassing clinical evaluation and imaging techniques. In cases where conservative management proves ineffective, embolization through conventional lymphangiography by bipedal dissection or intranodal injection emerges as a viable option. This review underscores the importance of a comprehensive approach to diagnosing and treating lymphatic leaks, highlighting advancements in imaging and therapeutic interventions that enhance patient outcomes.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"7 1","pages":"61"},"PeriodicalIF":1.2,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11316727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-03DOI: 10.1186/s42155-024-00472-4
Elisabeth R. Seyferth, Helen Song, Ansar Z. Vance, Timothy W. I. Clark
Statins are widely used in coronary and peripheral arterial disease, but their impact on patency of stents placed for peripheral arterial disease is not well-studied. The purpose of this study was to evaluate femoropopliteal stent primary patency according to statin intensity at the time of stent placement and compare this effect to other covariates that may influence stent patency. A retrospective review identified 278 discrete femoropopliteal stent constructs placed in 216 patients over a 10-year period; Rutherford categories were 2 (3.6%), 3 (12.9%), 4 (21.2%), 5 (49.6%), and 6 (12.6%). Stent locations were common femoral (1.8%), common femoral/superficial femoral (0.7%), superficial femoral (50.7%), superficial femoral/popliteal (32.7%) and popliteal (14.0%) arteries; 63.3% of stents were paclitaxel-eluting. Primary patency of each stent construct was determined with duplex ultrasound, angiography, or computed tomographic angiography. Greater than 50% restenosis or stent occlusion was considered loss of patency. Cox proportional hazard and Kaplan–Meier modeling were used to assess the effect of statin use and additional covariates on stent patency. Patients on any statin at the time of stent placement were half as likely to undergo loss of primary unassisted patency as patients on no statin therapy (hazard ratio, 0.53; 95% confidence interval, 0.19–0.87; P = .004). Moderate/high intensity statin therapy conferred 17 additional months of median stent patency compared to the no statin group. Antiplatelet therapy, anticoagulant therapy, drug-eluting stents (versus bare metal or covered stents), and Rutherford class were not predictive of stent patency (P = 0.52, 0.85, 0.58, and 0.82, respectively). Use of statin therapy at the time of femoropopliteal stent placement was the most predictive examined variable influencing primary unassisted patency.
{"title":"Association between statin intensity and femoropopliteal stent primary patency in peripheral arterial disease","authors":"Elisabeth R. Seyferth, Helen Song, Ansar Z. Vance, Timothy W. I. Clark","doi":"10.1186/s42155-024-00472-4","DOIUrl":"https://doi.org/10.1186/s42155-024-00472-4","url":null,"abstract":"Statins are widely used in coronary and peripheral arterial disease, but their impact on patency of stents placed for peripheral arterial disease is not well-studied. The purpose of this study was to evaluate femoropopliteal stent primary patency according to statin intensity at the time of stent placement and compare this effect to other covariates that may influence stent patency. A retrospective review identified 278 discrete femoropopliteal stent constructs placed in 216 patients over a 10-year period; Rutherford categories were 2 (3.6%), 3 (12.9%), 4 (21.2%), 5 (49.6%), and 6 (12.6%). Stent locations were common femoral (1.8%), common femoral/superficial femoral (0.7%), superficial femoral (50.7%), superficial femoral/popliteal (32.7%) and popliteal (14.0%) arteries; 63.3% of stents were paclitaxel-eluting. Primary patency of each stent construct was determined with duplex ultrasound, angiography, or computed tomographic angiography. Greater than 50% restenosis or stent occlusion was considered loss of patency. Cox proportional hazard and Kaplan–Meier modeling were used to assess the effect of statin use and additional covariates on stent patency. Patients on any statin at the time of stent placement were half as likely to undergo loss of primary unassisted patency as patients on no statin therapy (hazard ratio, 0.53; 95% confidence interval, 0.19–0.87; P = .004). Moderate/high intensity statin therapy conferred 17 additional months of median stent patency compared to the no statin group. Antiplatelet therapy, anticoagulant therapy, drug-eluting stents (versus bare metal or covered stents), and Rutherford class were not predictive of stent patency (P = 0.52, 0.85, 0.58, and 0.82, respectively). Use of statin therapy at the time of femoropopliteal stent placement was the most predictive examined variable influencing primary unassisted patency.","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"21 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141885012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-27DOI: 10.1186/s42155-024-00467-1
Ken Zhao, Sam Y. Son, Debkumar Sarkar, Ernesto G. Santos
Sinistral portal hypertension, also known as left-sided portal hypertension, is a rare cause of gastric variceal bleeding which occurs secondary to occlusion of the splenic vein. We present a case of venous occlusion and sinistral portal hypertension secondary to distal pancreatic cancer requiring treatment of gastric variceal bleeding. After failing conservative management, transvenous intervention was attempted, but a venous communication with the gastric varices was unable to be identified on multiple venograms. A percutaneous trans-splenic approach using a 21-G needle and ultrasound guidance was successful in directly accessing an intraparenchymal vein feeding the gastric varices, and glue embolization was performed directly through the access needle with excellent results.
窦性门静脉高压症又称左侧门静脉高压症,是继发于脾静脉闭塞的胃静脉曲张出血的罕见病因。我们报告了一例因远端胰腺癌继发静脉闭塞和窦状门静脉高压而需要治疗胃静脉曲张出血的病例。在保守治疗失败后,我们尝试了经静脉介入治疗,但多次静脉造影均无法确定胃静脉曲张的静脉通路。在超声引导下,使用 21 G 穿刺针经皮经脾穿刺,成功地直接进入了胃静脉曲张的实质内静脉,并直接通过穿刺针进行了胶水栓塞,取得了良好的效果。
{"title":"Trans-splenic percutaneous glue embolization of bleeding gastric varices in the setting of malignant sinistral portal hypertension","authors":"Ken Zhao, Sam Y. Son, Debkumar Sarkar, Ernesto G. Santos","doi":"10.1186/s42155-024-00467-1","DOIUrl":"https://doi.org/10.1186/s42155-024-00467-1","url":null,"abstract":"Sinistral portal hypertension, also known as left-sided portal hypertension, is a rare cause of gastric variceal bleeding which occurs secondary to occlusion of the splenic vein. We present a case of venous occlusion and sinistral portal hypertension secondary to distal pancreatic cancer requiring treatment of gastric variceal bleeding. After failing conservative management, transvenous intervention was attempted, but a venous communication with the gastric varices was unable to be identified on multiple venograms. A percutaneous trans-splenic approach using a 21-G needle and ultrasound guidance was successful in directly accessing an intraparenchymal vein feeding the gastric varices, and glue embolization was performed directly through the access needle with excellent results.","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"13 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141770901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-27DOI: 10.1186/s42155-024-00471-5
Eisen Liang, Razeen Parvez, Sylvia Ng, Bevan Brown
To report the effectiveness of uterine artery embolisation (UAE) in treating adenomyosis in women who failed prior endometrial ablation (EA).
Endometrial ablation (EA) is a minimally invasive treatment for heavy menstrual bleeding (HMB). Patient satisfaction rates for EA are around 80–90%; however, about 10–20% of women require additional intervention (re-ablation or hysterectomy) due to persistent bleeding or pain [1]. Women with adenomyosis are more likely to fail EA [2]. Those with unsatisfactory outcomes from EA may be offered hysterectomy as their only remaining treatment option. Case series and meta-analyses have demonstrated that UAE is effective in alleviating adenomyosis-related HMB and dysmenorrhea [3, 4]. However, the effectiveness of UAE in treating women who failed prior EA has not been previously reported. This is a retrospective cohort study of the outcome of UAE for adenomyosis in women who failed previous EA.
This study was approved by the institutional Human Research Ethics Committee. Informed consent was obtained from each participant. Women presenting to our clinic with significant dysmenorrhea and/or HMB following unsatisfactory endometrial ablation were offered UAE as an alternative to hysterectomy. Medical records of women who had UAE for adenomyosis at our institution between January 2017 and March 2022 were reviewed to identify those who had EA prior to UAE. All women had pre-UAE MRI to confirm the presence of adenomyosis, diagnosed based on previously published criteria: junctional zone thickness of ≥ 12 mm or > 40% of myometrial thickness, or the presence of T2 hyperintense cysts/foci/fissuring [5]. All UAE procedures were performed with non-spherical polyvinyl alcohol (nsPVA) particles as previously described [4], and with starting nsPVA size at 180–300 micron (Cook 200) or 150–250 micron (Boston Scientific) as suggested by the 1-2-3 Protocol [6]. To evaluate the clinical outcome, a 2-part online survey was sent to women via email link to complete at home. Part 1 inquired about symptoms, menopausal status, overall satisfaction, and requirement for further intervention (Appendix 1). Women who had heavy menstrual bleeding prior to UAE were asked about their periods at the time of the audit. Overall success rate of UAE was assessed by asking women if they were “Very Satisfied,” “Satisfied,” “Not sure,” “Not Satisfied,” or “Very Unsatisfied” about the outcome. Only women who rated “Very Satisfied” or “Satisfied” were regarded as overall successful. Part 2 consisted of the validated Uterine Fibroid Symptom and Quality of Life Survey (UFSQoL) [7]. The following parameters before UAE and at follow-up were recorded and compared: dysmenorrhea visual analogue scale (VAS) pain score, number of days with dysmenorrhea, symptom score, and QoL score (using UFSQoL). Uterine volume and junctional zone thickness at baseline MRI and 6 months follow-up were compared. Significance of changes before and after treatment was
子宫动脉栓塞治疗症状性腺肌症的有效性和安全性临床审核:117 名妇女的结果。Aust N Z J Obstet Gynaecol.2018;58:454-9.Article PubMed Google Scholar Agostinho L, Cruz R, Osório F, Alves J, Setúbal A, Guerra A. MRI for adenomyosis: a pictorial review.Insights Imaging.https://doi.org/10.1007/s13244-017-0576-z.Article PubMed PubMed Central Google Scholar Kim MD, Kim YM, Kim HC, Cho JH, Kang HG, Lee C, Kim HJ, Lee JT.子宫动脉栓塞治疗无症状子宫腺肌症:1-2-3方案的新技术发展和影响结果的磁共振成像预测因素。J Vasc Interv Radiol.2011; 22(4):497-502.Article PubMed Google Scholar Spies JB, Coyne K, Guaou Guaou N, et al. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata.Obstet Gynecol.2002;99(2):290-300.PubMed Google Scholar McCausland AM, McCausland VM.子宫腺肌症的子宫内膜穿透深度有助于确定滚珠消融术的结果。Am J Obstet Gynecol.1996;174:1786-94.Article CAS PubMed Google Scholar Daub CA, Sepmeyer JA, Hathuc V, Sakala MD, Caserta MP, Clingan MJ, Hosseinzadeh K. Endometrial ablation: normal imaging appearance and delayed complications.Am J Roentgenol.2015;205(4):W451-60.Article Google Scholar Champaneria R, Abedin P, Daniels J, Balogun M, Khan KS.超声扫描和磁共振成像诊断子宫腺肌症:比较检测准确性的系统综述。Acta Obstet Gynecol Scand.2010;89(11):1374-84.Article PubMed Google Scholar Download references无特别鸣谢。作者和单位悉尼纤维瘤诊所,澳大利亚悉尼Eisen Liang, Razeen Parvez &;Bevan BrownGosford Hospital, Gosford, NSW, AustraliaSylvia Ng作者Eisen Liang查看作者发表的论文您也可以在PubMed Google Scholar中搜索该作者Razeen Parvez查看作者发表的论文您也可以在PubMed Google Scholar中搜索该作者Sylvia Ng查看作者发表的论文您也可以在PubMed Google Scholar中搜索该作者Bevan Brown查看作者发表的论文您也可以在PubMed Google Scholar中搜索该作者作者贡献作者的贡献如下:Eisen Liang 的职责:设计概念、伦理提交、数据收集、文献综述、论文起草、提交。Razeen Parvez 的职责:数据收集、数据分析、文献检索、伦理呈文。Sylvia Ng 的职责:数据分析、文献检索、起草/格式化/参考文献;Bevan Brown 的职责:设计概念、文献综述、审稿和编辑:研究助理,医科学生:Sylvia Ng:研究助理,放射科实习生:伦理批准和参与同意本研究获得了所有参与者的知情同意。本研究获得了基督复临安息日会医疗保健有限公司人类研究伦理委员会(HREC 2022-028)的批准。同意发表我们同意在《CVIR Endovascular》上发表。出版商注释Springer Nature对已出版地图中的管辖权主张和机构隶属关系保持中立。补充材料1.开放获取本文采用知识共享署名 4.0 国际许可协议进行许可,该协议允许以任何媒介或格式使用、共享、改编、分发和复制,只要您适当注明原作者和来源,提供知识共享许可协议的链接,并说明是否进行了更改。本文中的图片或其他第三方材料均包含在文章的知识共享许可协议中,除非在材料的署名栏中另有说明。如果材料未包含在文章的知识共享许可协议中,且您打算使用的材料不符合法律规定或超出许可使用范围,则您需要直接从版权所有者处获得许可。如需查看该许可的副本,请访问 http://creativecommons.org/licenses/by/4.0/.Reprints and permissionsCite this articleLiang, E., Parvez, R., Ng, S. et al. Uterine artery embolisation for adenomyosis in women who failed prior endometrial ablation.https://doi.org/10.1186/s42155-024-00471-5Download citationReceived:08 June 2024Accepted:10 July 2024Published: 27 July 2024DOI: https://doi.org/10.1186/s42155-024-00471-5Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative.
{"title":"Uterine artery embolisation for adenomyosis in women who failed prior endometrial ablation","authors":"Eisen Liang, Razeen Parvez, Sylvia Ng, Bevan Brown","doi":"10.1186/s42155-024-00471-5","DOIUrl":"https://doi.org/10.1186/s42155-024-00471-5","url":null,"abstract":"<p>To report the effectiveness of uterine artery embolisation (UAE) in treating adenomyosis in women who failed prior endometrial ablation (EA).</p><p>Endometrial ablation (EA) is a minimally invasive treatment for heavy menstrual bleeding (HMB). Patient satisfaction rates for EA are around 80–90%; however, about 10–20% of women require additional intervention (re-ablation or hysterectomy) due to persistent bleeding or pain [1]. Women with adenomyosis are more likely to fail EA [2]. Those with unsatisfactory outcomes from EA may be offered hysterectomy as their only remaining treatment option. Case series and meta-analyses have demonstrated that UAE is effective in alleviating adenomyosis-related HMB and dysmenorrhea [3, 4]. However, the effectiveness of UAE in treating women who failed prior EA has not been previously reported. This is a retrospective cohort study of the outcome of UAE for adenomyosis in women who failed previous EA.</p><p>This study was approved by the institutional Human Research Ethics Committee. Informed consent was obtained from each participant. Women presenting to our clinic with significant dysmenorrhea and/or HMB following unsatisfactory endometrial ablation were offered UAE as an alternative to hysterectomy. Medical records of women who had UAE for adenomyosis at our institution between January 2017 and March 2022 were reviewed to identify those who had EA prior to UAE. All women had pre-UAE MRI to confirm the presence of adenomyosis, diagnosed based on previously published criteria: junctional zone thickness of ≥ 12 mm or > 40% of myometrial thickness, or the presence of T2 hyperintense cysts/foci/fissuring [5]. All UAE procedures were performed with non-spherical polyvinyl alcohol (nsPVA) particles as previously described [4], and with starting nsPVA size at 180–300 micron (Cook 200) or 150–250 micron (Boston Scientific) as suggested by the 1-2-3 Protocol [6]. To evaluate the clinical outcome, a 2-part online survey was sent to women via email link to complete at home. Part 1 inquired about symptoms, menopausal status, overall satisfaction, and requirement for further intervention (Appendix 1). Women who had heavy menstrual bleeding prior to UAE were asked about their periods at the time of the audit. Overall success rate of UAE was assessed by asking women if they were “Very Satisfied,” “Satisfied,” “Not sure,” “Not Satisfied,” or “Very Unsatisfied” about the outcome. Only women who rated “Very Satisfied” or “Satisfied” were regarded as overall successful. Part 2 consisted of the validated Uterine Fibroid Symptom and Quality of Life Survey (UFSQoL) [7]. The following parameters before UAE and at follow-up were recorded and compared: dysmenorrhea visual analogue scale (VAS) pain score, number of days with dysmenorrhea, symptom score, and QoL score (using UFSQoL). Uterine volume and junctional zone thickness at baseline MRI and 6 months follow-up were compared. Significance of changes before and after treatment was","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"37 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141770902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-23DOI: 10.1186/s42155-024-00466-2
Asaad Osman, Raj Das, Ana Pinas, Richard Hartopp, Deborah Livermore, Benjamin Hawthorn, Joo-Young Chun, Leto Mailli, Robert Morgan, Lakshmi Ratnam
Purpose: To evaluate outcomes and complications of prophylactic internal iliac balloon occlusion (PIIBO) in the management of patients with placenta accreta spectrum (PAS) at a large regional referral centre.
Materials and methods: A retrospective review of all PIIBO for PAS performed over a 12-year period (2010-2022). Information for analysis was gathered from the local RIS/PACS and clinical documentation. Collected data included patient demographics, indication for procedure, sheath insertion and removal time, total duration of balloon inflation and complications that occurred.
Results: 106 patients underwent temporary internal iliac artery balloon occlusion within the 12-year period. All procedures utilised bilateral common femoral artery punctures, 6Fr sheath and 5Fr Le Maitre occlusion balloons. Catheters were successfully positioned and balloons inflated in obstetric theatre following caesarean delivery in 100% of the cases. The uterus was conserved in every case. There was no maternal mortality or foetal morbidity. Twenty patients (18.9%) had some form of complication that required further intervention. Of these, 7(6.6%) had post-operative PPH, which was treated with uterine artery embolisation; and 13 (12.3%) had arterial thrombus which required aspiration thrombectomy. All procedures were technically successful with no long-term sequelae.
Conclusion: PIIBO plays an important part in reducing morbidity and mortality in patients with PAS. Clear pathways and multidisciplinary team working is critical in the management of these patients to ensure that any complications are dealt with promptly to avoid long-term sequelae.
目的:评估一家大型地区转诊中心在治疗胎盘早剥谱系(PAS)患者时采用预防性髂内球囊闭塞术(PIIBO)的效果和并发症:对 12 年内(2010-2022 年)为 PAS 实施的所有 PIIBO 进行回顾性分析。用于分析的信息来自当地的 RIS/PACS 和临床文件。收集的数据包括患者的人口统计学特征、手术指征、鞘插入和拔出时间、球囊充气的总持续时间以及发生的并发症:12年间,106名患者接受了临时髂内动脉球囊闭塞术。所有手术均采用双侧股总动脉穿刺、6Fr鞘和5Fr Le Maitre闭塞球囊。100%的病例都是在剖腹产后的产科病房成功定位导管并为球囊充气。每个病例都保留了子宫。没有产妇死亡或胎儿发病。20 名患者(18.9%)出现了某种形式的并发症,需要进一步干预。其中,7 例(6.6%)术后出现 PPH,需要进行子宫动脉栓塞治疗;13 例(12.3%)出现动脉血栓,需要进行抽吸血栓切除术。所有手术在技术上都很成功,没有长期后遗症:PIIBO在降低PAS患者的发病率和死亡率方面发挥着重要作用。明确的路径和多学科团队合作对这些患者的管理至关重要,可确保及时处理任何并发症,避免长期后遗症。
{"title":"Outcome evaluation of prophylactic internal iliac balloon occlusion in the management of patients with placenta accreta spectrum.","authors":"Asaad Osman, Raj Das, Ana Pinas, Richard Hartopp, Deborah Livermore, Benjamin Hawthorn, Joo-Young Chun, Leto Mailli, Robert Morgan, Lakshmi Ratnam","doi":"10.1186/s42155-024-00466-2","DOIUrl":"10.1186/s42155-024-00466-2","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate outcomes and complications of prophylactic internal iliac balloon occlusion (PIIBO) in the management of patients with placenta accreta spectrum (PAS) at a large regional referral centre.</p><p><strong>Materials and methods: </strong>A retrospective review of all PIIBO for PAS performed over a 12-year period (2010-2022). Information for analysis was gathered from the local RIS/PACS and clinical documentation. Collected data included patient demographics, indication for procedure, sheath insertion and removal time, total duration of balloon inflation and complications that occurred.</p><p><strong>Results: </strong>106 patients underwent temporary internal iliac artery balloon occlusion within the 12-year period. All procedures utilised bilateral common femoral artery punctures, 6Fr sheath and 5Fr Le Maitre occlusion balloons. Catheters were successfully positioned and balloons inflated in obstetric theatre following caesarean delivery in 100% of the cases. The uterus was conserved in every case. There was no maternal mortality or foetal morbidity. Twenty patients (18.9%) had some form of complication that required further intervention. Of these, 7(6.6%) had post-operative PPH, which was treated with uterine artery embolisation; and 13 (12.3%) had arterial thrombus which required aspiration thrombectomy. All procedures were technically successful with no long-term sequelae.</p><p><strong>Conclusion: </strong>PIIBO plays an important part in reducing morbidity and mortality in patients with PAS. Clear pathways and multidisciplinary team working is critical in the management of these patients to ensure that any complications are dealt with promptly to avoid long-term sequelae.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"7 1","pages":"57"},"PeriodicalIF":1.2,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11263516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141749649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-20DOI: 10.1186/s42155-024-00470-6
Peng Hu, Guangwen Chen, Jingpeng Wei, Rengui Huang, Yaochang Luo
Background: Ulcer erosion into the cystic artery is a rare cause of bleeding in duodenal ulcers, with only a limited number of cases described in the literature. Historically, treatment has predominantly involved surgical intervention. We present three cases of duodenal ulcer bleeding due to cystic artery erosion, which were successfully managed with cystic artery embolization.
Case presentation: This case series includes three male patients with duodenal ulcer bleeding, aged 90, 81, and 82 years, respectively, and no prior history of biliary system disorders. The ulcer locations were identified as two in the post-bulbar region and one in the anterior bulb. After the failure of medical and endoscopic treatment, transcatheter arterial embolization was adopted. Initial angiography did not reveal any contrast medium extravasation. Empirical embolization of the gastroduodenal artery using gelatin sponge particles and coils failed to achieve hemostasis. Super-selective cystic artery angiography confirmed the source of bleeding as the cystic artery. One patient was embolized with gelatin sponge particles and coils, while the other two patients were embolized with N-butyl-cyanoacrylate. All patients achieved successful hemostasis without gallbladder infraction.
Conclusions: Cystic artery embolization proved to be a minimally invasive technique for achieving hemostasis in these cases, indicating that it may be a safe and effective alternative to surgery for this uncommon cause of upper gastrointestinal bleeding. Validation through further studies is warranted.
{"title":"Transcatheter embolization for duodenal ulcer bleeding originating from cystic artery erosion.","authors":"Peng Hu, Guangwen Chen, Jingpeng Wei, Rengui Huang, Yaochang Luo","doi":"10.1186/s42155-024-00470-6","DOIUrl":"10.1186/s42155-024-00470-6","url":null,"abstract":"<p><strong>Background: </strong>Ulcer erosion into the cystic artery is a rare cause of bleeding in duodenal ulcers, with only a limited number of cases described in the literature. Historically, treatment has predominantly involved surgical intervention. We present three cases of duodenal ulcer bleeding due to cystic artery erosion, which were successfully managed with cystic artery embolization.</p><p><strong>Case presentation: </strong>This case series includes three male patients with duodenal ulcer bleeding, aged 90, 81, and 82 years, respectively, and no prior history of biliary system disorders. The ulcer locations were identified as two in the post-bulbar region and one in the anterior bulb. After the failure of medical and endoscopic treatment, transcatheter arterial embolization was adopted. Initial angiography did not reveal any contrast medium extravasation. Empirical embolization of the gastroduodenal artery using gelatin sponge particles and coils failed to achieve hemostasis. Super-selective cystic artery angiography confirmed the source of bleeding as the cystic artery. One patient was embolized with gelatin sponge particles and coils, while the other two patients were embolized with N-butyl-cyanoacrylate. All patients achieved successful hemostasis without gallbladder infraction.</p><p><strong>Conclusions: </strong>Cystic artery embolization proved to be a minimally invasive technique for achieving hemostasis in these cases, indicating that it may be a safe and effective alternative to surgery for this uncommon cause of upper gastrointestinal bleeding. Validation through further studies is warranted.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"7 1","pages":"56"},"PeriodicalIF":1.2,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141728279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-18DOI: 10.1186/s42155-024-00468-0
Kolos Turtóczki, Hyunsoo Cho, Sorour Dastaran, Pál N Kaposi, Zoltán Tömösváry, Szabolcs Várbíró, Nándor Ács, Ildikó Kalina, Viktor Bérczi
Background: Uterine artery embolisation is a recommended method of adenomyosis treatment with good clinical results. Changes in uterine volume and maximal junctional zone thickness (JZmax) after embolisation are thoroughly analyzed in the literature. In contrast changes in other suggested morphological diagnostic markers of adenomyosis (junctional zone differential / JZdiff-and junctional zone ratio / JZratio) are rarely evaluated. This single-centre retrospective study aimed to analyse the changes in morphological parameters used for the MR imaging diagnosis of adenomyosis (including JZdiff and JZratio) after UAE. Clinical effectiveness and safety were also analysed.
Materials and methods: Patients who underwent UAE for pure adenomyosis from Jan 2008 to Dec 2021 were evaluated. Adenomyosis was diagnosed based on JZmax, JZdiff, and JZratio measured on MR imaging. To assess clinical efficacy, the numerical-analog-quality-of-life (QoL) score was routinely obtained from patients at our centre. MRI morphological data were analysed. Statistical analysis was conducted using Wilcoxon signed-rank test, uni- and multivariate regression models, Pearson product-moment correlation, and Kruskal-Wallis tests.
Results: From our database of 801 patients who underwent UAE between Jan 2008 to Dec 2021, preprocedural MR images were available in 577 cases and, 15 patients had pure adenomyosis (15/577, 2.6%). Uterine volume, JZmax, and JZdiff decreased significantly after UAE; QoL score increased significantly. A significant correlation was found between QoL change vs. JZmax and JZdiff change. Permanent amenorrhoea and elective hysterectomy 5 years after UAE were both 7.1%.
Conclusion: Change of JZdiff after UAE in adenomyosis is a potential marker of clinical success. UAE is a clinically safe and effective treatment for adenomyosis.
{"title":"Evaluation of junctional zone differential and ratio as possible markers of clinical efficacy in uterine artery embolisation of adenomyosis.","authors":"Kolos Turtóczki, Hyunsoo Cho, Sorour Dastaran, Pál N Kaposi, Zoltán Tömösváry, Szabolcs Várbíró, Nándor Ács, Ildikó Kalina, Viktor Bérczi","doi":"10.1186/s42155-024-00468-0","DOIUrl":"10.1186/s42155-024-00468-0","url":null,"abstract":"<p><strong>Background: </strong>Uterine artery embolisation is a recommended method of adenomyosis treatment with good clinical results. Changes in uterine volume and maximal junctional zone thickness (JZmax) after embolisation are thoroughly analyzed in the literature. In contrast changes in other suggested morphological diagnostic markers of adenomyosis (junctional zone differential / JZdiff-and junctional zone ratio / JZratio) are rarely evaluated. This single-centre retrospective study aimed to analyse the changes in morphological parameters used for the MR imaging diagnosis of adenomyosis (including JZdiff and JZratio) after UAE. Clinical effectiveness and safety were also analysed.</p><p><strong>Materials and methods: </strong>Patients who underwent UAE for pure adenomyosis from Jan 2008 to Dec 2021 were evaluated. Adenomyosis was diagnosed based on JZmax, JZdiff, and JZratio measured on MR imaging. To assess clinical efficacy, the numerical-analog-quality-of-life (QoL) score was routinely obtained from patients at our centre. MRI morphological data were analysed. Statistical analysis was conducted using Wilcoxon signed-rank test, uni- and multivariate regression models, Pearson product-moment correlation, and Kruskal-Wallis tests.</p><p><strong>Results: </strong>From our database of 801 patients who underwent UAE between Jan 2008 to Dec 2021, preprocedural MR images were available in 577 cases and, 15 patients had pure adenomyosis (15/577, 2.6%). Uterine volume, JZmax, and JZdiff decreased significantly after UAE; QoL score increased significantly. A significant correlation was found between QoL change vs. JZmax and JZdiff change. Permanent amenorrhoea and elective hysterectomy 5 years after UAE were both 7.1%.</p><p><strong>Conclusion: </strong>Change of JZdiff after UAE in adenomyosis is a potential marker of clinical success. UAE is a clinically safe and effective treatment for adenomyosis.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"7 1","pages":"55"},"PeriodicalIF":1.2,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11258104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141635713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}